Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F)(the “Company” or “Isodiol”) is set to debut its newest CBD raw ingredient, Heneplex p200™, at Supply Side West in Las Vegas November 8th and 9th, 2018, booth 1557, to meet the new demand and market trend in the beverage sector.

Heneplex p200™ has the advantage of being far more versatile than traditional CBD hemp extracts and oils, which can be difficult to formulate and use to manufacture consumer good products. CBD hemp extract in an oil form sticks to just about everything, tastes bad to many users, and dissolves in few substances besides alcohols and oils. In short, formulating with CBD hemp extracts is challenging. p200™ by contrast, can simply be mixed into food and beverage products, almost without exception, including protein shakes, juices, soda, coff­ee, tea, baked goods or frozen goods, or simply added to a glass of water.


Management would also like to provide an update to its shareholders around the volatility of the stock and would like to address recent investor inquiries. The Company has not deviated from its business plan announced on June 29, 2018 and believes it is executing on its business strategies in each division with new revenue opportunities being added on a consistent basis. Further, management believes some of the Company’s business strategies are in front of market trends that will soon be recognized by the market, particularly as legalization continues to trend in a favourable direction in the United States and Mexico.

Due to recent developments with the US Hemp Bill, the Company has postponed plans of its previously announced Chinese facility expansion plans and has been focusing its resources and attention to the expected upcoming opportunities in the United States and Mexico.

On December 6, 2017, the Company announced the 100% acquisition of CN Pharma, located in Abbotsford, BC, a pharmaceutical manufacturing company. The Company believed that CN Pharma was in the latter stages of obtaining its Licensed Dealer (“LD”) status under the provisions of the Canadian Controlled Drugs and Substances, however many changes to regulatory guidelines have caused a delay. CN Pharma has reapplied for their licensing under these new cannabis regulations and is ready for inspection. The Company is hoping to receive additional feedback from Health Canada after inspection and believes CN Pharma remains in a position to obtain its license. CN Pharma will only be paid the $6,000,000 CDN in stock upon successful completion of obtaining the license.

The Company is monitoring the developing regulations surrounding CBD in Canada and believes it will be in a position for the distribution of its products in this market as regulations continue to change. Currently, the Company can supply CBD as an API to an LD in Canada from its subsidiary, BSPG Laboratories, LTD. The Company strongly believes the U.S. and other foreign markets such as the U.K. and Brazil will surpass the market opportunities in Canada that are currently getting stock market attention and as a result, Isodiol will continue to put much of its focus on the U.S. and markets outside of Canada.

Finally, the Company had previously announced its intention to up list to a major US Exchange and this intention has not changed. The Company continues to explore all of its options for a potential up listing. Further updates on this matter will be provided as they are available.

Follow Our Corporate Updates On Facebook: https://www.facebook.com/IsodiolInternationalInc/ and on Twitter: @Isodiolintlinc

Get Social with Our Brands:

https://www.facebook.com/isodiol/
https://www.instagram.com/isodiol/?hl=en
https://www.instagram.com/isosportnow/?hl=en
https://www.instagram.com/pot.o.coffee/
https://www.instagram.com/cbdxtreme/
https://www.instagram.com/shopbradleys/?hl=en

ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director

INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com

Media Contact:
Christopher Hussey
Director of Communications
media@isodiol.com

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.

Click here to connect with Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) for an Investor Presentation. 

Source: globenewswire.ca

American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.

Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.

Keep reading... Show less

An Emerging Markets Sponsored Commentary

Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.

Keep reading... Show less

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less